Business Wire

AI Innovation and Strategic DAM Deployments Fuel Record First Half for Bynder

24.7.2024 16:00:00 EEST | Business Wire | Press release

Share

Bynder, a global leader in enterprise digital asset management (DAM), has revealed how the accelerated adoption of the company’s AI-powered solutions and strategic DAM deployments have driven record growth in the first half of 2024.

More than 350 customers have adopted Bynder’s enhanced AI Search Experience since its launch nine months ago, and through the solution, more than 30 million images have been processed. Bynder, which currently has over 150 million active assets on its platform, also reported that in the first half of the year, it has seen a 20% year-on-year increase in the delivery of assets to connected systems. With assets delivered 113 billion times in the first half of the year, this shows that Bynder’s customers are continuing to leverage content as a strategic differentiator to deliver exceptional content experiences.

Bynder first integrated AI into its platform in 2016, demonstrating the company’s long-term commitment well before it became mainstream. Since then, Bynder has accelerated its efforts by acquiring an AI company and launching AI Search Experience, continually enhancing its AI capabilities and giving customers governance and control over how AI is used in their organizations and on their own terms.

Since the launch of Bynder’s AI Search Experience, many of Bynder's customers have adopted the solution, reinforcing the trend that AI is increasingly viewed as a strategic tool for marketers seeking to streamline content operations and improve customer experience. This trend validates Bynder's approach to AI, demonstrating the need to harness AI responsibly to deliver tangible benefits to its customers.

Bynder’s AI-powered DAM platform is pivotal in supporting go-to-market operations and the adoption of AI within content operations has driven the rapid uptake of Bynder’s AI Search Experience. This solution is customer-inspired and enables teams to maximize asset reuse, save resources, reduce time spent searching for assets, and automatically eliminate duplicates.

The benefits of the solution were evidenced at Bynder’s recent customer Spotlight Awards where brands such as Viator, Les Mills and Inspire Brands were recognized for their excellence in innovation, creating compelling value and return on investment when it comes to the implementation and use of Bynder DAM.

By leveraging AI-powered recommendations and filtering options, Inspire Brands was able to quickly locate and distribute relevant assets across its portfolio of sub-brands. This new level of findability has promoted content reuse within the organization and increased the value of the assets that the company invests in.

Cliff Crosbie, Head of AI Strategies at Bynder, said: “It’s great to see that our ongoing innovation and market leadership in AI has continued to drive growth in the first half of this year, along with our strategic DAM deployments which have both become invaluable solutions for our customers. The digital landscape continues to evolve faster than ever, so it’s our aim to implement AI responsibly to help drive scale and efficiency and we’re looking forward to bringing the next phase of our AI enhancements to market very soon.”

As a result of the company’s accelerated growth, Bynder has appointed Ann-Michèle Verheyden as its new Chief Legal Officer. Ann-Michèle brings extensive experience in SaaS, IP and privacy, supporting Bynder’s position and investment in AI where she will be building a robust compliance framework enabling businesses to navigate the complexities of AI-driven technology while mitigating risk.

Richard Heitmann also joins Bynder as its new Chief Marketing Officer. Richard brings a wealth of experience from high-growth startups like Aspera and enterprise software experience from IBM. Richard’s expertise will help drive further growth and bring Bynder’s platform innovations to the market.

Looking forward to the second half of the year, Bynder will host its inaugural customer event, Bynder Connect, in September in Amsterdam. The event will bring together industry leaders to share insights, launch new innovations, and celebrate successes with its customers.

For more information on Bynder’s AI-powered DAM, please visit: https://www.bynder.com/en/solutions/initiatives/ai-automation/

View source version on businesswire.com: https://www.businesswire.com/news/home/20240724434819/en/

Contacts

Manisha Mehta / manisha.mehta@bynder.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release

Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release

Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release

For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro

Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release

Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye